p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and -Independent Mechanisms

REFERENCES

• Gupta GP, Massague J. 2006. Cancer metastasis: building a framework. Cell 127:679–695.
   PubMed Web of Science ®Google Scholar
• Fidler IJ. 2003. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3:453–458.
   PubMed Web of Science ®Google Scholar
• Kang S, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, Xiong L, Wang D, Muller S, Fan S, Sun SY, Marcus AI, Gu TL, Polakiewicz RD, Chen GZ, Khuri FR, Shin DM, Chen J. 2010. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Invest. 120:1165–1177.
   PubMed Web of Science ®Google Scholar
• Blenis J. 1993. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. U. S. A. 90:5889–5892.
   PubMed Web of Science ®Google Scholar
• Frodin M, Gammeltoft S. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151:65–77.
   PubMed Web of Science ®Google Scholar
• Fisher TL, Blenis J. 1996. Evidence for two catalytically active kinase domains in pp90rsk. Mol. Cell. Biol. 16:1212–1219.
   PubMed Web of Science ®Google Scholar
• Buck M, Poli V, Hunter T, Chojkier M. 2001. C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol. Cell 8:807–816.
   PubMed Web of Science ®Google Scholar
• He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z. 2003. Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J. Biol. Chem. 278:10588–10593.
   PubMed Web of Science ®Google Scholar
• Palmer A, Gavin AC, Nebreda AR. 1998. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. EMBO J. 17:5037–5047.
   PubMed Web of Science ®Google Scholar
• Shimamura A, Ballif BA, Richards SA, Blenis J. 2000. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 10:127–135.
   PubMed Web of Science ®Google Scholar
• Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, Dustin M, Huang DC, Taunton J, Pagano M. 2009. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell 33:109–116.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z, Chung LW. 2007. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26:5070–5077.
   PubMedGoogle Scholar
• Jean D, Bar-Eli M. 2000. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 212:19–28.
   PubMedGoogle Scholar
• Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, Hinrichs SH, Bar-Eli M. 2000. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19:2721–2730.
   PubMedGoogle Scholar
• Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. 1998. CREB and its associated proteins act as survival factors for human melanoma cells. J. Biol. Chem. 273:24884–24890.
   PubMedGoogle Scholar
• Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M. 1997. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15:2069–2075.
   PubMed Web of Science ®Google Scholar
• Xing J, Ginty DD, Greenberg ME. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959–963.
   PubMed Web of Science ®Google Scholar
• Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. 2001. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21:893–901.
   PubMed Web of Science ®Google Scholar
• Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC, Min W. 2005. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24:3954–3963.
   PubMed Web of Science ®Google Scholar
• Gu JJ, Wang Z, Reeves R, Magnuson NS. 2009. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28:4261–4271.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Zhang C, Shokat KM, Taunton J. 2005. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308:1318–1321.
   PubMed Web of Science ®Google Scholar
• Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J. 2007. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12:201–214.
   PubMed Web of Science ®Google Scholar
• Kang S, Dong S, Guo A, Ruan H, Lonial S, Khoury HJ, Gu TL, Chen J. 2008. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and Src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J. Biol. Chem. 283:4652–4657.
   PubMed Web of Science ®Google Scholar
• Kang S, Elf S, Dong S, Hitosugi T, Lythgoe K, Guo A, Ruan H, Lonial S, Khoury HJ, Williams IR, Lee BH, Roesel JL, Karsenty G, Hanauer A, Taunton J, Boggon TJ, Gu TL, Chen J. 2009. Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol. Cell. Biol. 29:2105–2117.
   PubMed Web of Science ®Google Scholar
• Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J. 2011. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 44:864–877.
   PubMed Web of Science ®Google Scholar
• Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98:31–36.
   PubMed Web of Science ®Google Scholar
• Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. 2005. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 65:1027–1034.
   PubMed Web of Science ®Google Scholar
• Aubele M, Vidojkovic S, Braselmann H, Ritterswurden D, Auer G, Atkinson MJ, Tapio S, Hofler H, Rauser S, Bartlett JM. 2009. Overexpression of PTK6 (breast tumor kinase) protein—a prognostic factor for long-term breast cancer survival—is not due to gene amplification. Virchows Arch. 455:117–123.
   PubMedGoogle Scholar
• Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Yu M, Miller WT, Muthuswamy SK. 2008. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105:12463–12468.
   PubMed Web of Science ®Google Scholar
• Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. 2006. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol. Ther. 5:1136–1141.
   PubMed Web of Science ®Google Scholar
• Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. 2010. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5:e11729. doi:10.1371/journal.pone.0011729.
   PubMed Web of Science ®Google Scholar
• Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. 2008. The new tumor suppressor genes ING: genomic structure and status in cancer. Int. J. Cancer 123:1483–1490.
   PubMedGoogle Scholar
• Campos EI, Chin MY, Kuo WH, Li G. 2004. Biological functions of the ING family tumor suppressors. Cell. Mol. Life Sci. 61:2597–2613.
   PubMedGoogle Scholar
• Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T, Nagai N, Nishizaki K, Shimizu K. 2002. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21:4462–4470.
   PubMed Web of Science ®Google Scholar
• Richards HW, Medrano EE. 2009. Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 22:14–29.
   PubMedGoogle Scholar
• Wang Y, Dai DL, Martinka M, Li G. 2007. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res. 13:4111–4116.
   PubMedGoogle Scholar
• Wang Y, Li G. 2006. ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J. Biol. Chem. 281:11887–11893.
   PubMedGoogle Scholar